Reviewing Organigram Global (NASDAQ:OGI) and Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) and Organigram Global (NASDAQ:OGI) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for Abbott Laboratories and Organigram Global, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0	5	21	2	2.89
Organigram Global	0	1	2	0	2.67

Abbott Laboratories presently has a consensus price target of $118.32, suggesting a potential upside of 8.18%. Given Abbott Laboratories’ stronger consensus rating and higher probable upside, research analysts clearly believe Abbott Laboratories is more favorable than Organigram Global.

Earnings and Valuation

This table compares Abbott Laboratories and Organigram Global”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$48.23 billion	3.93	$6.52 billion	$2.68	40.81
Organigram Global	$185.07 million	0.65	-$17.70 million	$0.46	1.86

Abbott Laboratories has higher revenue and earnings than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abbott Laboratories and Organigram Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	9.75%	18.04%	9.09%
Organigram Global	28.14%	-13.39%	-8.67%

Insider & Institutional Ownership

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 34.6% of Organigram Global shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.1% of Organigram Global shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Abbott Laboratories has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Organigram Global has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.

Summary

Abbott Laboratories beats Organigram Global on 12 of the 14 factors compared between the two stocks.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

About Organigram Global

Organigram Global Inc. is a Canadian cannabis company that develops, produces and sells cannabis products for adult-use recreational and medical markets. The company offers dried flower, pre-rolls, cannabis beverages, vapes, edibles and concentrates under a portfolio of brands that has included Edison, SHRED, Big Bag O’ Buds, Trailblazer, Monjour and Laurentian. Organigram operates in Canada through cultivation, processing and manufacturing facilities, including its main production operations in Moncton, New Brunswick.